Published date: 14 September 2021
Last edited date: 14 September 2021
This notice was replaced on 21 October 2021
This notice does not contain the most up-to-date information about this procurement. The most recent notice is:
Future opportunity (published 21 October 2021)
Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.
Contract summary
Industry
Pharmaceutical products - 33600000
Location of contract
United Kingdom, Isle of Man, Channel Islands
Value of contract
£600,000
Procurement reference
CM/PHS/21/5645
Published date
14 September 2021
Approach to market date
1 February 2022
Contract start date
1 July 2022
Contract end date
30 June 2023
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
Recombinant Von Willebrand Factor
Period of framework agreement: 1 July 2022 to 30 June 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months
More information
Spend profile
| Financial year | Budget |
|---|---|
| 2022/2023 | £450,000 |
| 2023/2024 | £150,000 |
About the buyer
Contact name
Karen Bell
Address
Rutland House
Runcorn
WA7 2ES
England
Share this notice
All content is available under the
